List of Excipients in Branded Drug ELOCON

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme Corp	ELOCON	mometasone furoate	0085-0370	HEXYLENE GLYCOL
Merck Sharp & Dohme Corp	ELOCON	mometasone furoate	0085-0370	PETROLATUM
Merck Sharp & Dohme Corp	ELOCON	mometasone furoate	0085-0370	PHOSPHORIC ACID
Merck Sharp & Dohme Corp	ELOCON	mometasone furoate	0085-0370	PROPYLENE GLYCOL MONOPALMITOSTEARATE

ELOCON Excipient Strategy: Formulation, Generic Entry, and Commercial Opportunities for Mometasone Furoate

Last updated: August 13, 2026

ELOCON is a topical corticosteroid containing mometasone furoate 0.1%. Its commercial opportunity is concentrated in formulation differentiation rather than active-ingredient exclusivity. The U.S. products include cream, ointment, and lotion dosage forms, each using a distinct excipient system to control spreadability, evaporation, occlusion, residue, and patient acceptability. Core U.S. composition patents and regulatory exclusivities are no longer the primary barriers to entry. The strongest opportunities are low-irritancy generics, improved sensory performance, pediatric formulations, combination products, and differentiated delivery systems.

What is ELOCON and which formulations are commercially available?

ELOCON is a prescription topical corticosteroid indicated for inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. The active ingredient is mometasone furoate at a concentration of 0.1% [1].

Product	Dosage form	Strength	Primary formulation profile
ELOCON Cream	Cream	0.1%	Emulsion with emollient, structuring, absorbent, and opacifying excipients
ELOCON Ointment	Ointment	0.1%	Petrolatum-based, highly occlusive formulation
ELOCON Lotion	Lotion	0.1%	Lower-viscosity vehicle designed for spreadability and hairy or larger body areas

The products are associated with Organon and were originally approved in the United States under NDA 019097. U.S. labeling identifies the products as mometasone furoate topical formulations rather than systemic drug products [1,2].

What excipients are used in ELOCON cream, ointment, and lotion?

The excipient profile differs materially by dosage form. That difference creates the main formulation-development opportunities.

ELOCON cream excipients

U.S. labeling identifies the following inactive ingredients in ELOCON Cream 0.1%:

• Aluminum starch octenylsuccinate
• Ceteareth-20
• Hexylene glycol
• Phosphoric acid
• Purified water
• Stearyl alcohol
• Titanium dioxide
• White wax
• White petrolatum

The cream system uses fatty alcohols, waxes, and petrolatum to provide body and emolliency. Ceteareth-20 functions as an emulsifying surfactant. Aluminum starch octenylsuccinate can improve dry feel and reduce the greasy character associated with petrolatum. Titanium dioxide contributes opacity and visual uniformity [1].

ELOCON ointment excipients

ELOCON Ointment 0.1% uses a simpler, more occlusive vehicle. The listed excipients include:

• Hexylene glycol
• Phosphoric acid
• Propylene glycol stearate
• Purified water
• White wax
• White petrolatum

White petrolatum and white wax create the primary occlusive matrix. Propylene glycol stearate contributes emolliency and vehicle structure. The ointment is likely to provide stronger barrier effects than the lotion, but it can have greater greasiness, transfer, and patient-acceptability limitations [1].

ELOCON lotion excipients

ELOCON Lotion 0.1% uses a lower-viscosity vehicle containing:

• Hydroxypropyl cellulose
• Isopropyl alcohol
• Phosphoric acid
• Purified water
• Sodium phosphate monobasic monohydrate

Hydroxypropyl cellulose provides viscosity and suspension or solution control. Isopropyl alcohol supports rapid evaporation and a lighter sensory profile. The alcohol-containing system may improve spreadability but can cause stinging on fissured, excoriated, or inflamed skin [1].

Formulations and inactive ingredients can differ by country, manufacturing site, and labeling update. Product developers must use the applicable current reference product label and FDA inactive-ingredient database when designing a U.S. generic.

How does the ELOCON excipient system affect product performance?

The active ingredient alone does not determine the commercial performance of a topical corticosteroid. Excipient selection affects drug release, skin hydration, residence time, application feel, transfer, and adherence.

Excipient function	ELOCON formulation example	Commercial effect
Occlusion	White petrolatum, white wax	Increases hydration and residence time; may feel greasy
Emulsification	Ceteareth-20	Supports cream stability and uniformity
Viscosity and structure	Stearyl alcohol, hydroxypropyl cellulose	Controls spreadability, pourability, and dose uniformity
Dry-feel improvement	Aluminum starch octenylsuccinate	Reduces oily after-feel in cream systems
Volatile solvent	Isopropyl alcohol	Speeds drying; may increase sting
pH control	Phosphoric acid, sodium phosphate	Supports formulation stability and skin compatibility
Emolliency	Propylene glycol stearate, petrolatum	Improves softness and barrier feel
Appearance	Titanium dioxide	Provides opacity and visual consistency

The cream and ointment are more suitable for dry or thickened lesions where moisturization and occlusion are commercially relevant. The lotion is better positioned for scalp, hairy areas, and larger application surfaces where a greasy vehicle creates adherence problems.

What formulation patents protect ELOCON?

No active U.S. patent barrier is generally associated with the original ELOCON cream, ointment, and lotion products today. The original product approvals date to the late 1980s and early 1990s, placing the original composition and regulatory exclusivity periods well behind current generic-development timelines [2,3].

The relevant competitive barriers are now:

1. Abbreviated New Drug Application requirements.
2. Demonstration of pharmaceutical equivalence.
3. Demonstration of bioequivalence under FDA topical-product standards.
4. Manufacturing capability for semisolid and lotion dosage forms.
5. Stability, microbial quality, preservative control, and packaging performance.
6. Potential patent or regulatory protection for later-developed delivery systems.

A company developing a materially different vehicle should avoid relying on the reference product's formulation history as evidence of freedom to operate. New patents may cover novel emulsions, polymers, nanoparticles, spray systems, packaging, or combination products even when mometasone furoate itself is off patent.

When does ELOCON lose exclusivity and what is the Orange Book status?

ELOCON's original exclusivity has expired. The product is commercially exposed to generic competition through FDA's ANDA pathway.

Regulatory issue	ELOCON position
Active ingredient	Mometasone furoate
U.S. reference product	ELOCON
Original U.S. approval	1987 for the principal NDA product [2]
Dosage forms	Cream, ointment, lotion
Current exclusivity relevance	Original exclusivity expired
Generic pathway	ANDA, subject to product-specific FDA requirements
Biosimilar pathway	Not applicable
Orange Book relevance	Listed drug and patent-certification framework may apply to listed products and associated patents

Topical products can present more complex generic-development issues than conventional oral tablets. FDA may assess formulation sameness, Q1/Q2 similarity, product performance, and, where applicable, dermatopharmacokinetic or in vitro release characteristics. FDA's guidance for topical dermatological products identifies in vitro release testing as an important development tool for demonstrating comparative performance [4].

What Paragraph IV challenges and litigation affect ELOCON?

Paragraph IV litigation risk is lower than it was during the original patent-protected period because the principal ELOCON exclusivity period has expired. A generic applicant may still file a Paragraph IV certification if it identifies an unexpired listed patent that it believes is invalid, unenforceable, or not infringed.

No specific current Paragraph IV dispute should be assumed without checking the FDA Orange Book, ANDA litigation records, and federal court dockets at the time of launch planning. A topical generic can also face litigation over:

• A later-listed formulation patent
• A method-of-use patent
• A device or applicator patent
• A combination product
• A manufacturing process
• Trade dress or product packaging

Settlement agreements are commercially relevant only if an unexpired patent remains enforceable and the settlement includes a defined generic entry date, authorized-generic terms, or supply arrangements. The original ELOCON product history does not itself establish a current settlement barrier.

What commercial opportunities exist for ELOCON excipient innovation?

Low-irritancy lotion and gel vehicles

The ELOCON lotion uses isopropyl alcohol, which supports rapid drying but may sting compromised skin. A nonalcoholic or reduced-alcohol vehicle could target patients who reject conventional lotions because of burning or drying.

Potential excipient platforms include:

• Hydroxypropyl cellulose and other cellulose polymers
• Carbomer or acrylate rheology modifiers
• Phospholipid or lamellar emulsions
• Glycol-reduced systems
• Silicone-based spreading agents
• Humectant-controlled aqueous gels

The development objective would be comparable drug delivery with better tolerability and cosmetic acceptance.

Reduced-grease cream systems

The reference cream contains white petrolatum, waxes, stearyl alcohol, and aluminum starch octenylsuccinate. A generic or follow-on product could reduce residue through:

• Lightweight emollient esters
• Volatile or semi-volatile silicones
• Alternative starch-based sensory modifiers
• Lamellar emulsions
• Lower-petrolatum oil phases
• Airless packaging that improves dosing and cleanliness

The commercial value is strongest in chronic or recurrent dermatitis, where patients may discontinue treatment because of poor cosmetic feel.

Advanced ointment systems

The ointment has a high-occlusion profile. A differentiated product could use a barrier-repair vehicle containing ceramide-compatible lipids, cholesterol, fatty acids, or structured lipid systems. The product would need to preserve mometasone furoate stability and demonstrate acceptable release.

A barrier-repair positioning could support premium pricing, but claims must remain within the approved labeling unless supported through a new regulatory pathway.

Pediatric and sensitive-skin formulations

Mometasone furoate is a potent topical corticosteroid, and pediatric use requires careful attention to potency, treated surface area, duration, and systemic absorption. Excipients that reduce sting, fragrance exposure, sensitization risk, and residue can support pediatric and sensitive-skin positioning.

Potential differentiation includes:

• Fragrance-free formulations
• Essential-oil-free formulations
• Reduced-ethanol or alcohol-free lotion
• Short ingredient lists
• Preservative-minimized packaging
• Airless pumps and metered-dose dispensers

These changes do not eliminate corticosteroid safety requirements. They can improve usability and adherence if the final product remains pharmaceutically and clinically acceptable.

Scalp, intertriginous, and hairy-area delivery

Lotion is the most logical reference dosage form for scalp and hairy areas. Commercial alternatives include:

• Foam
• Spray
• Solution
• Pump applicator
• Nozzle-directed scalp package
• Low-residue gel

A foam or spray may command a higher price than a standard cream or ointment, but it introduces device, flammability, microbial, packaging, and process-validation requirements. A new dosage form may require a 505(b)(2) application rather than an ANDA if it does not meet the reference product's sameness requirements.

How does ELOCON compare with competing topical corticosteroids?

ELOCON competes with topical corticosteroids such as hydrocortisone, triamcinolone acetonide, betamethasone dipropionate, fluocinonide, and clobetasol propionate. The principal commercial variables are potency, dosage form, disease site, prescription status, price, and vehicle acceptability.

Product class	Typical commercial position	Excipient opportunity
Hydrocortisone	Lower potency, broad consumer familiarity	Sensitive-skin and OTC sensory improvements
Triamcinolone acetonide	High-volume generic corticosteroid	Low-cost, broad vehicle portfolio
Mometasone furoate	Potent prescription corticosteroid with cream, ointment, and lotion history	Improved sensory profile and targeted delivery
Betamethasone products	Potency and combination-product competition	Combination vehicles and specialty packaging
Clobetasol propionate	Very high potency, short-duration use	High-performance delivery with strict safety positioning

Mometasone furoate has a commercially useful middle position: stronger than low-potency corticosteroids but less specialized than ultra-high-potency products. Its three established vehicles provide a platform for generic substitution and line extension.

What manufacturing and intellectual-property barriers exist?

The main manufacturing barriers are technical rather than raw-material scarcity.

Semisolid manufacturing

Cream and ointment production requires control of:

• Heating and cooling profiles
• Emulsion droplet size
• Homogenization
• Active-ingredient dispersion
• Air incorporation
• Viscosity
• Fill weight
• Container compatibility

Mometasone furoate is present at 0.1%, making content uniformity and dispersion control important. Scale-up can change rheology and drug-release performance even when the qualitative formula appears similar.

Lotion manufacturing

Lotion products require control of:

• Polymer hydration
• Alcohol-water ratio
• Viscosity
• pH
• Suspension or solution state
• Evaporation during filling
• Container closure integrity

Hydroxypropyl cellulose systems can show viscosity changes with solvent composition, temperature, and mixing history.

Intellectual property

Potentially protectable features in a new ELOCON-related product include:

• Novel excipient combinations
• Controlled-release topical systems
• Foam or spray delivery
• Scalp-specific applicators
• Barrier-repair combinations
• Preservative-free packaging
• Manufacturing processes
• Stability-enhancing packaging
• New therapeutic uses

A strong patent estate would require claims that cover more than routine excipient substitution. Broad claims to a known active ingredient in a conventional cream are vulnerable to obviousness and written-description challenges.

What generic launch scenarios exist for ELOCON?

Three launch models are commercially realistic.

Low-cost ANDA generic

This model closely matches the reference product's dosage form and composition. It has the shortest development path but faces price competition and limited differentiation.

Formulation-differentiated generic

This model targets improved spreadability, reduced greasiness, reduced sting, or better packaging. It may obtain commercial differentiation but must satisfy FDA equivalence requirements and may face a more complex development program.

Follow-on delivery product

A foam, spray, scalp solution, or barrier-repair product may support premium pricing and broader licensing value. The regulatory pathway may be a 505(b)(2) application, depending on the product's differences from the reference drug.

Revenue exposure for the brand is difficult to isolate because ELOCON sales are not generally disclosed as a separate public reporting line. The largest commercial risk is substitution by low-cost mometasone furoate generics. The largest opportunity is a differentiated vehicle that improves adherence and supports payer, physician, or patient preference.

Key Takeaways

• ELOCON contains mometasone furoate 0.1% and is marketed in cream, ointment, and lotion forms.
• The cream uses petrolatum, waxes, fatty alcohols, ceteareth-20, and aluminum starch octenylsuccinate.
• The ointment is the most occlusive vehicle and has the highest potential for greasiness and transfer.
• The lotion uses hydroxypropyl cellulose and isopropyl alcohol for a lighter, faster-drying profile.
• Original ELOCON exclusivity has expired, making generic competition the primary commercial threat.
• The strongest excipient opportunities are nonstinging lotions, low-residue creams, advanced barrier-repair ointments, and scalp-focused delivery systems.
• Biosimilar risk does not apply because mometasone furoate is a small-molecule active ingredient.
• New delivery systems may require a 505(b)(2) pathway and separate patent and device strategies.
• Formulation development must address comparative release, rheology, stability, microbial quality, packaging, and patient acceptability.

FAQs

Is ELOCON cream preservative-free?

The U.S. ELOCON cream label does not identify a conventional antimicrobial preservative among its listed inactive ingredients. The final regulatory status depends on the current approved label and manufacturing configuration.

Can a generic ELOCON use different excipients?

Yes. An ANDA product can use different inactive ingredients if it satisfies applicable FDA requirements, does not introduce unacceptable safety concerns, and demonstrates pharmaceutical equivalence and bioequivalence.

Is mometasone furoate suitable for a foam formulation?

Mometasone furoate can be developed in alternative topical vehicles, but a foam would require evaluation of active dispersion, propellant or foam-base compatibility, drug release, stability, packaging, flammability, and the appropriate FDA pathway.

Which ELOCON dosage form has the greatest excipient differentiation potential?

The lotion and cream have the greatest sensory differentiation potential. The lotion can be redesigned to reduce alcohol-related stinging, while the cream can be redesigned to reduce greasiness and improve dry feel.

Can ceramides be added to a mometasone furoate product?

Ceramides may be technically compatible with a topical corticosteroid vehicle, but they create additional formulation, stability, microbial, labeling, and regulatory considerations. A ceramide-containing product may fall outside a simple ANDA strategy if the formulation or claims materially differ from the reference product.

References

1. Organon & Co. (n.d.). ELOCON (mometasone furoate) cream, ointment, and lotion prescribing information. U.S. Food and Drug Administration labeling repository.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: ELOCON, NDA 019097. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2022). Draft guidance for industry: Topical dermatologic corticosteroids: In vitro release test studies. Center for Drug Evaluation and Research.